Chief executives of ASX-listed biotechnology companies have warned Victoria could fall short of its aspirations to use its medical research expertise to revive the state's economy if it focuses on big names like CSL rather than boosting startups.
Chief executive of ASX-listed prescription management business MedAdvisor, Robert Read, said the focus on leveraging medical technologies for an economic recovery was exciting, but not enough focus was being placed on the digital technologies behind the scenes. "Now is not the time to just do what we have done before. This [fund] could literally transform Victoria's future. If it just reinvests back into traditional manufacturing, the sector will always be strong, but we’re missing out," she said.
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.